Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer

Bray, 2018, Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 68, 394, 10.3322/caac.21492 Locher, 2013, Major changes in lung cancer over the last ten years in France: the KBP-CPHG studies, Lung Cancer, 81, 32, 10.1016/j.lungcan.2013.03.001 Postmus, 2017, Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up, Ann Oncol, 28, iv1, 10.1093/annonc/mdx222 Antonia, 2017, Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer, N Engl J Med, 377, 1919, 10.1056/NEJMoa1709937 Antonia, 2018, Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC, N Engl J Med, 379, 2342, 10.1056/NEJMoa1809697 Lammering, 2001, Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization, J Natl Cancer Inst, 93, 921, 10.1093/jnci/93.12.921 Pujol, 2014, Meta-analysis of individual patient data from randomized trials of chemotherapy plus cetuximab as first-line treatment for advanced non-small-cell lung cancer, Lung Cancer, 83, 211, 10.1016/j.lungcan.2013.11.006 Raben, 2005, The effects of cetuximab alone and in combination with radiation and/or chemotherapy in lung cancer, Clin Cancer Res, 11, 795, 10.1158/1078-0432.795.11.2 Pirker, 2012, EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study, Lancet Oncol, 13, 33, 10.1016/S1470-2045(11)70318-7 Simon, 1989, Optimal two-stage designs for phase II clinical trials, Control Clin Trials, 10, 1, 10.1016/0197-2456(89)90015-9 Mazarella, 2018, Cetuximab for treating non-small-cell lung cancer, Expert Opin Biol Ther, 18, 483, 10.1080/14712598.2018.1452906 Jatoi, 2010, A phase II study of cetuximab and radiation in elderly and/or poor performance status patients with locally advanced non-small-cell lung cancer (N0422), Ann Oncol, 21, 2040, 10.1093/annonc/mdq075 Govindan, 2011, Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407, J Clin Oncol, 29, 3120, 10.1200/JCO.2010.33.4979 Bradley, 2015, Lancet Oncol, 16, 187, 10.1016/S1470-2045(14)71207-0 Bradley, 2019, Long-term results of NRG Oncology RTOG 0617: standard- versus high-dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small-cell lung cancer, J Clin Oncol, 38, 706, 10.1200/JCO.19.01162 Senan, 2016, PROCLAIM: randomized phase III trial of pemetrexed-cisplatin or etoposide-cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced non-squamous non-small-cell lung cancer, J Clin Oncol, 34, 953, 10.1200/JCO.2015.64.8824 Van Cutsem, 2011, Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status, J Clin Oncol, 29, 2011, 10.1200/JCO.2010.33.5091 Bonner, 2010, Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival, Lancet Oncol, 11, 21, 10.1016/S1470-2045(09)70311-0 Pirker, 2009, Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial, Lancet, 373, 1525, 10.1016/S0140-6736(09)60569-9 Mazzarella, 2018, Cetuximab for treating non-small-cell lung cancer, Expert Opin Biol Ther, 18, 483, 10.1080/14712598.2018.1452906 Ferris, 2018, Rationale for combination of therapeutic antibodies targeting tumor cells and immune checkpoint receptors: harnessing innate and adaptive immunity through IgG1 isotype immune effector stimulation, Cancer Treat Rev, 63, 48, 10.1016/j.ctrv.2017.11.008